More than 115 biotech companies have announced layoffs this year, on track to easily surpass 2022’s numbers. While this is not a new trend, the current trajectory is concerning, as it portends more difficult times ahead for the pharmaceutical industry–already in the midst of a major upheaval. It should also…
On August 29th, the Biden Administration named the 10 drugs that will be subject to price negotiation with Medicare in the initial implementation of the Inflation Reduction Act (IRA) of 2022. Release of the list marked a milestone in a decades-long effort by Democrats to use the purchasing power of…
Long-term success in any industry requires ongoing investment to progress customer-facing capabilities and internal operations. Health insurance is no exception and – one could argue – due to often thin differences among competitors, is a side of the health care ecosystem where smart reinvestment can create the margin to win…
As the adage goes: “The more things change, the more they stay the same.” This certainly holds true for healthcare delivery. Today, health systems are attempting to reinvent themselves again – either by changing their name, logo, North Star vision or all of the above – to better reflect what…
Population health management has been a national topic of conversation, but to date little effort has been devoted to tracking the actual progress that’s been made toward this new model of care. Now in its seventh year, Numerof’s State of Population Health survey provides an in-depth, national look at the pace…
As our Numerof 2023 Global Pharma Outlook infographic illustrates, this year’s story for pharmaceutical manufacturers will be about continuing to adapt to pressures on price, especially mandated government negotiation, and demands for value while dealing with the long-term effects of the pandemic.
